Brokerages Set AstraZeneca PLC (LON:AZN) Target Price at GBX 6,303.50

AstraZeneca PLC (LON:AZN) has been assigned an average rating of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is GBX 6,303.50 ($83.05).

A number of analysts have recently weighed in on AZN shares. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Tuesday, April 29th. Berenberg Bank restated a “buy” rating and set a GBX 140 ($1.84) price objective on shares of AstraZeneca in a research report on Wednesday, March 26th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Wednesday, February 19th.

AstraZeneca Trading Up 0.3%

Shares of AZN opened at £102.72 ($135.34) on Friday. AstraZeneca has a twelve month low of GBX 9,573.51 ($126.13) and a twelve month high of £133.88 ($176.39). The stock’s fifty day simple moving average is £108.59 and its 200 day simple moving average is £109.07. The firm has a market capitalization of £197.64 billion, a P/E ratio of 28.16, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.